Curated News
By: NewsRamp Editorial Staff
January 02, 2025
ABVC BioPharma Secures Patent Approval for ADHD Treatment in Taiwan
Discuss on Reddit
LinkedIn
Substack
TelegramTLDR
- Patent approval for Polygala extract in ADHD treatment strengthens ABVC BioPharma's global IP portfolio, giving a competitive edge in natural therapies market.
- ABVC's patent application for Polygala extract targets ADHD symptoms through Norepinephrine Transporter inhibition, offering a novel approach to treatment.
- ABVC's innovative ADHD therapy aims to enhance patient outcomes globally, reflecting a commitment to advancing care for those with ADHD.
- ABVC's patent approval in Taiwan for Polygala extract showcases breakthrough in ADHD treatment, paving the way for future advancements in neurology and ophthalmology.
Impact - Why it Matters
This news matters as ABVC BioPharma's innovative treatment for ADHD has the potential to significantly impact the global ADHD treatment market, which is projected to reach $32.14 billion by 2030. The approval of this patent marks a milestone in the company's commitment to advancing ADHD care and providing a novel therapeutic option for patients inadequately managed by existing therapies.
Summary
ABVC BioPharma, Inc. secures patent approval in Taiwan for Polygala Extract to treat ADHD, adding to previous US and Australian patents. The treatment targets ADHD core symptoms through Norepinephrine Transporter inhibition. The company plans to leverage the patent to expand global reach and improve outcomes for patients worldwide.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, ABVC BioPharma Secures Patent Approval for ADHD Treatment in Taiwan
